What diseases is Acalatinib/Acalatinib mainly used to treat?

Akatinib (Acalatinib) is mainly used to treat specific hematological cancer diseases, and its efficacy and safety have been verified in clinical studies.

Acotinib is widely used to treat mantle cell lymphoma, a rare form of non-Hodgkin lymphoma that is often clinically aggressive. The drug is particularly suitable for use in adult patients who have received at least one prior therapy. In China, this indication was approved in March 2023, providing a new treatment option for this type of patients.

In addition to mantle cell lymphoma, acotinib is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma. Both diseases are hematological malignancies that have a significant impact on patients' quality of life and survival. By inhibiting the B cell signaling pathway, acotinib reduces the incidence of leukemia and other diseases, thereby prolonging the survival period and improving the quality of life of patients. In China, this indication was approved on September 1, 2023, bringing new hope to these patients.

The efficacy of acotinib has been fully verified in clinical trials. For example, in a global clinical study, acotinib showed significant efficacy in adult patients with MCL who had received at least one prior therapy. In addition, the drug has a relatively high safety profile, with relatively few and mild side effects, which allows patients to better tolerate the treatment and adhere to the medication.

Acotinib (Acalatinib) is mainly used to treat mantle cell lymphoma and chronic lymphocytic leukemia/Small lymphocytic lymphoma. Its efficacy and safety are supported by clinical studies, providing new treatment options for patients with these diseases.